NCT06987539View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 29, 2025

Primary Completion Date

January 4, 2030

Study Completion Date

January 4, 2030

Conditions
Generalized Myasthenia Gravis
Interventions
DRUG

Inebilizumab

Inebilizumab will be administered IV.

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT06987539 - A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG) | Biotech Hunter | Biotech Hunter